Royal DSM N.V. announces that in accordance with the share buy-back
program published on 27 September 2007 the company will today, 1
October 2007, start the first phase of this EUR 750 million program.
DSM has signed a Discretionary Management Agreement with the bank
that will execute the share buy-back.
In 2007 DSM intends to repurchase shares for a total consideration of
up to EUR 250 million. The remainder of the program will be executed
in 2008, subject to the approval of the Annual Meeting of
Shareholders in March 2008.
The repurchase price will be based on the daily VWAP (Value Weighted
Average Price). Daily volumes to be repurchased will be around 10% of
the daily trading volume. In accordance with the present regulations
DSM will regularly inform the market via press releases about the
progress made in the execution of this share buy-back program.
DSM
DSM creates innovative products and services in life sciences and
materials sciences, contributing to the quality of life. DSM's
products and services are used globally in a wide range of markets
and applications, supporting a healthier, more sustainable and
enjoyable way of living. End markets include human and animal
nutrition and health, personal care, pharmaceuticals, automotive,
coatings and paint, electrics & electronics, life protection and
housing. The company strategy, Vision 2010 - Building on Strengths,
focuses on accelerating profitable and innovative growth of the
company's specialties portfolio. The key drivers of this strategy are
market-driven growth and innovation, an increased presence in
emerging economies and operational excellence. DSM has annual sales
of almost
EUR 9 billion and employs some 22,000 people worldwide. The company
is headquartered in the Netherlands, with locations in Europe, Asia,
the Americas, Africa and Australia. More information on DSM can be
found at www.dsm.com.
For more information:
DSM Corporate Communications DSM Investor Relations
Elvira Luykx Dries Ausems
tel. +31 (0) 45 tel. +31 (0) 45 5782864
5782035 fax +31 (0) 45 5782595
fax +31 (0) 45 e-mail
5740680 investor.relations@dsm.com
e-mail media.relations@dsm.com
